培菲康对重症急性胰腺炎疗效及对TNF-α及SOD水平的影响

Abstract
Figure/Table
References
Related Citation (1)

Download: PDF (495 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To explore the efficacy of Bifid-triple viable Capsules (Bifico) for severe acute pancreatitis (SPA) and its effects on tumor necrosis factor-α (TNF-α) and superoxide dismutase (SOD) levels.Methods Eighty-two patients with SPA admitted to our hospital from December 2014 to February 2017 were included in the study,and were assigned by random number table,the control group including 40 patients were received conventional care,the observation group including 42 patients were received conventional care combined with Bifico introduced on the day of admission,both for 7 days.The two groups were compared for clinical efficacy.Results Treatment resulted in decreases in TNF-α and Amy and increases in SOD in both groups,which were more significant in the observation group (P<0.05);the time to first flatus,time to first defecation and time to relief of abdominal pain were shorter in the observation group (P<0.05);the overall response was higher in the observation group (92.86%) than that in the control group (72.50%) (P<0.05).Conclusion Bifico provides significant efficacy for the treatment of SPA,as it resulted in better improvement in the inflammatory reactions and better recovery of the gastrointestinal function,supporting its further application.

Key words： Bifico Severe acute pancreatitis N inflammatory factors SOD Gastrointestinal function recovery

Received: 04 July 2017

PACS:

R657.5

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	CHEN Xiang-sheng
	XIAO Qing-hua
	LIU Su-hua

Cite this article:

CHEN Xiang-sheng,XIAO Qing-hua,LIU Su-hua. Efficacy of Bifid-triple viable Capsules for severe acute pancreatitis and its effect on TNF-α and SOD levels[J]. 中国当代医药, 2017, 24(24): 69-71.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2017/V24/I24/69

[1]	康利民,潘明新,高毅,等.肠内免疫微生态营养对重症急性胰腺炎患者免疫功能及治疗效果的影响[J].实用医学杂志,2013,29（18）：6014-6016.
[2]	王德会.乌司他丁辅助治疗急性胰腺炎的疗效和安全性分析[J].临床合理用药,2015,8（8）：69-70.
[3]	张炎.中西医结合治疗急性重症胰腺炎并发肠功能障碍疗效观察[J].现代中西医结合杂志,2014,23（13）：1416-1418.
[4]	中华医学会外科学分会胰腺外科学组.急性胰腺炎诊治指南（2014）[J].中华肝胆外科杂志,2015,21（1）：1-4.
[5]	李宗军.奥曲肽联合加贝酯治疗重症急性胰腺炎临床疗效的初步探讨[J].重庆医科大学学报,2013,38（7）：810-812.
[6]	姜莉,孙正令,张银华.十四肽生长抑素联合乌司他丁治疗急性重症胰腺炎的临床观察[J].中国药房,2012,23（36）：3414-3416.
[7]	吴云,周亚魁.生长抑素对急性胰腺炎血液流变学影响的实验研究[J].中华普通外科杂志,2013,14（6）：427-429.
[8]	赵中江,邓哲,孙冀武,等.痰热清注射液对重症急性胰腺炎大鼠肺损伤保护作用的初步研究[J].中国中医急症,2015,24（4）：604-606.
[9]	吕培华.早期应用培菲康治疗急性重症胰腺炎的临床疗效及对炎症因子的影响[J].实用临床医药杂志,2013,17（19）：17-20.
[10]	邓康.双歧三联活菌胶囊联合美沙拉秦对溃疡性结肠炎患者T淋巴细胞亚群及细胞因子的影响[J].中国医学前沿杂志（电子版）,2015,7（2）：58-60.
[11]	冯维智.乌司他丁联合方案治疗急性胰腺炎合并肺损伤疗效观察[J].海南医学,2014,25（17）：2585-2584.
[12]	郑建,吕望,郑忠盛.乌司他丁联合参麦注射液治疗急性胰腺炎相关肺损伤的临床研究[J].医学研究杂志,2014, 43（12）：111-113.
[13]	任英霞,康惠贞.乌司他丁、生长抑素联合泮托拉唑钠对急性重症胰腺炎患者炎症因子的影响[J].中国医刊,2014,49（12）：64-65.
[14]	宫健伟,叶蕾,张秀丽,等.地黄饮子对脑缺血再灌注模型大鼠血清、脑组织SOD,CAT和GSH-Px及MDA的影响[J].中国实验方剂学杂志,2013,19（14）：247-250.
[15]	马瑞松,李元红,周晓亚,等.过氧化氢通过上调高迁移率族蛋白损伤心肌的实验研究[J].疑难病杂志,2015,14（6）：551-555.
[16]	张魁,田文静,朱云亮,等.依那普利治疗老年脑血栓患者的疗效及其对内皮素-1和超氧化物歧化酶水平的影响[J].疑难病杂志,2016,15（6）：563-566.
[17]	曾杰,陈宁波,胡卫健.奥曲肽联合加贝酯治疗重症急性胰腺炎的疗效及对患者胃肠功能和血清细胞因子的影响[J].中国老年学杂志,2014,34（17）：4744-4746.